Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia
Table 1
Correlation of FZD6 expression with clinical characteristics in AML patients.
FZD6 high ()
FZD6 low ()
Sex, (%)
0.490
Female
38 (44.2)
43 (49.4)
Male
48 (55.8)
44 (50.6)
Age, years
0.818
Median (range)
58 (21-88)
58 (18-82)
WBC (×109/L)
0.985
Median (range)
14.7 (0.5-223.8)
14.5 (0.4-297.4)
BM blasts (%)
0.001
Median (range)
67 (30-100)
78 (32-100)
PB blasts (%)
0.099
Median (range)
48 (0-97)
25 (0-98)
CRC, (%)
<0.001
Favorable
9 (10.7)
23 (26.7)
Intermediate
44 (52.4)
57 (66.3)
Poor
31 (36.9)
6 (7.0)
ELN risk stratification, (%)
<0.001
Favorable
9 (10.7)
24 (27.9)
Intermediate
41 (48.8)
51 (59.3)
Adverse
34 (39.5)
11 (13.0)
Induction therapy, (%) #
0.910
Intensive
66 (80.5)
69 (81.2)
Nonintensive
16 (19.5)
16 (18.8)
HSCT, (%)
0.003
Yes
46 (53.5)
27 (31.0)
No
40 (46.5)
60 (69.0)
Gene mutation
FLT3, (%)
20 (23.3)
29 (33.3)
0.141
TP53, (%)
13 (15.1)
1 (1.2)
<0.001
DNMT3A, (%)
23 (26.7)
19 (21.8)
0.451
NPM1, (%)
9 (10.5)
37 (42.5)
<0.001
RUNX1, (%)
10 (11.6)
5 (5.8)
0.188
ASXL1, (%)
3 (3.49)
0 (0)
0.121
IDH1, (%)
9 (10.5)
8 (9.2)
0.804
IDH2, (%)
9 (10.5)
7 (8.1)
0.611
The total patient number is 170 for three patients are lacking evaluable cytogenetic or molecular Information. #Total patient number is 167 for six patients who did not receive any treatment after diagnosis. Intensive treatment means the induction therapy regimen is abased on regimens. Nonintensive treatment means epigenetic therapy and low-intensive treatment. Abbreviations: WBC, white blood cell; BM, bone marrow; PB, peripheral blood; CRC, cytogenetic risk classification; ELN, European Leukemia Net; HSCT, hematopoietic stem cell transplantation.
